Its role in cancer has been recently reviewed38 and the action of the anticancer drug N-bromoacetiletanolamine is based on targeting the enzyme PFK-2, involved in the synthesis and degradation of fructose-2,6-biphosphate. This evidence concerns the gene PFKFB3 and cancer.